Replies to post #509 on HemaCare Corp. (fka HEMA)

[dg33]

Finally, a voice in the wilderness.

Clearly, someone or a number of people found out what we've known for a while. The CEO's letter to shareholders https://www.hemacare.com/wp-content/uploads/2018/05/2017-Annual-Report_Final.pdf is a worthwhile read, especially this line-- "we continue transforming HemaCare to become the preferred supplier of human biological materials supporting immunotherapy, cell therapy, and regenerative medicine worldwide. We look forward to maximizing the future of the company and all the potential it holds". Their industry is predicted to have a $2.5B market value in 2024.

They are more than doubling their operational space, increasing efficiency of product development, expanding to a far greater degree into markets worldwide and buying new state of the art equipment.

I have no idea what the shares will be selling for in 2 years but given that the company is under the radar and has yet to be up listed (I believe they are focusing on growing the company and will let the share price take care of itself, rather than focusing attention where it's not needed at the moment), the future could be as exciting as what we've experienced over the past 2 years.